Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia

Miguel, Sol Cortés de; Calleja‐Hernández, Miguel Ángel; Menjón-Beltrán, Salomón; Vallejo-Rodríguez, Inmaculada

doi:10.1007/s00520-014-2459-x

Cited by 16 publications

(10 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cortes de Miguel et al identificaron que los pacientes con diagnóstico de linfoma no Hodgkin exhiben un mayor riesgo para el desarrollo de NF, debido a los diferentes grados y variantes histológicas de la enfermedad y al requerimiento de esquemas múltiples y/o agresivos de QT. [14][15][16] Es importante tener en cuenta que el mayor riesgo de NF se documenta en el primer ciclo de QT, disminuyendo en ciclos posteriores. 17 Bongiovanni et al describieron que el uso de Filgrastim en pacientes con leucemia linfoblástica aguda después de una QT intensiva, reducía significativamente la duración de la neutropenia y los tiempos de hospitalización respecto al grupo control (mediana de 16 vs 32 días [p <0.001] y 22 vs 28 días [p= 0.02].…”

Section: Discussionunclassified

“…Describen que la incidencia de neutropenia febril fue del 16 % y la duración del tratamiento de 11.5 días (media) cuando se administró Filgrastim por 24 horas, después de una dosis de ciclofosfamida, mientras que la tasa de NF aumentó 66 % junto con la duración del tratamiento por 15.5 días, cuando se inició Filgrastim por 96 horas después de la QT. 16 Un retraso en la administración de Filgrastim durante más de 72 horas dio lugar a episodios febriles y mayor uso de antibióticos. 16 Los G-CSF estimulan la proliferación y diferenciación de neutrófilos a partir de sus células progenitoras, induciendo su maduración y supervivencia, 20,21 reduciendo de esta manera la incidencia, duración y severidad de estos eventos de neutropenia [20][21][22] y de las complicaciones asociadas como la NF y la morbimortalidad por infecciones.…”

Section: Discussionunclassified

See 1 more Smart Citation

Estudio FIRES: Filgrastim - investigación retrospectiva de efectividad y seguridad en una institución de salud en Colombia

Fontalvo¹,

Esteban²,

Esteban³

et al. 2023

Rev.Col.Hematol.Oncol

View full text Add to dashboard Cite

La quimioterapia (QT) como forma de tratamiento de las neoplasias provoca neutropenia, neutropenia febril y mielosupresión, lo que favorece la presentación de infecciones, sepsis, muerte y una menor respuesta inmunitaria. Los factores estimulantes de colonias son una alternativa terapéutica que mejora la supervivencia y la respuesta inmunitaria de los pacientes con neoplasias. Métodos: se llevó a cabo un estudio observacional retrospectivo analítico en pacientes con neoplasias atendidos en una institución de salud especializada entre los años 2017 y 2019 en la ciudad de Bogotá y tratados con Filgrastim, que presentaron neutropenia febril, abordando la respuesta clínica y seguridad en términos de aumento de neutrófilos. Resultados: la muestra estuvo comprendida por 133 pacientes, se encontró que los pacientes tuvieron mayor cantidad de complicaciones por linfoma no Hodgkin con un 44.4 % (n=59), seguido por leucemia 36.1 % (n=48) y otros tumores 12 % (n=16), de los cuales el 29 % (n=38) se clasificó en el estadio 4, el 12 % (n=16) en estadio 3 y el 9 % (n=12) en estadio 2 de su patología neoplásica. El grupo de pacientes tratados con Filgrastim presentó un aumento en el recuento de neutrófilos posterior al inicio de tratamiento (p= 0.04). Conclusiones: la neutropenia febril se presenta en cualquier edad, siendo más frecuente en la sexta década de vida. El Filgrastim demostró ser un medicamento efectivo y seguro, como parte de la intervención terapéutica en pacientes con diagnóstico oncológico bajo esquemas de QT, representando mejoría del recuento de neutrófilos.

show abstract

Section: Discussionunclassified

Estudio FIRES: Filgrastim - investigación retrospectiva de efectividad y seguridad en una institución de salud en Colombia

Fontalvo¹,

Esteban²,

Esteban³

et al. 2023

Rev.Col.Hematol.Oncol

View full text Add to dashboard Cite

show abstract

“…Myeloid growth factor (MGF) such as recombinant human granulocyte colony-stimulating factor (rhG-CSF) is currently used to treat and prevent CIM [ 6 ]. The use of MGF can improve disease-free survival (DFS) and overall survival (OS) in breast cancer [ 7 ]. The WBC-increasing effect is fast but rather short-lived.…”

Section: Introductionmentioning

confidence: 99%

The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study

Zhang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. The randomized controlled clinical trial aims to investigate the clinical efficacy of moxibustion for breast cancer patients with chemotherapy-induced myelosuppression (CIM) during adjuvant chemotherapy. Methods. Surgically resected breast cancer patients were randomly divided into the moxibustion group (MOX; n = 48) and control group (CON; n = 44). Routine adjuvant chemotherapy (every 21 days, 4–8 cycles) and supportive recombinant human granulocyte colony-stimulating factor were given to both groups, while MOX received an additional moxibustion treatment (once daily after each cycle of chemotherapy). Primary endpoints included the grade of myelosuppression in terms of white blood cell (WBC) and absolute neutrophil count (ANC) and the incidence of myelosuppression-related serious adverse events (SAEs). Other measures included treatment compliance, adverse events (AEs), and survival. Results. WBC counts were generally higher in MOX and were dramatically higher than those in CON at the 7th course of chemotherapy ( P = 0.008 ), while grade 1 ANC reduction was dramatically lower than that in CON at the 7thcourse of chemotherapy ( P = 0.006 ). These effects were particularly significant in patients receiving anthracycline-taxane combination regimens. Moreover, MOX had fewer febrile neutropenia than CON ( P = 0.051 ). MOX demonstrated a lower incidence of grade 3–4 myelosuppression ( P < 0.05 ). AEs including grade 2–3 severe nausea, various kinds of pains, and vertigo occurred less frequently in MOX ( P < 0.05 ). No difference in survival was observed between the two groups ( P > 0.05 ). Conclusion. Moxibustion is effective for treating CIM in breast cancer patients during adjuvant chemotherapy, especially for patients receiving high-dose, long-term, and combined chemotherapy regimens. Moxibustion can reduce the incidence of myelosuppression-related SAE and improve the compliance and safety of chemotherapy in breast cancer.

show abstract

“…Adjuvant TAC chemotherapy is accompanied by high incidence of FN [ 12 ]. Primary prophylaxis with pegfilgrastim during adjuvant TAC and other high risk treatments is now covered by the Korean National Health Insurance System.…”

Section: Introductionmentioning

confidence: 99%

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy

Lee

Kim

et al. 2018

Ann Surg Treat Res

View full text Add to dashboard Cite

PurposePrimary prophylaxis with granulocyte colony-stimulating factor can effectively prevent febrile neutropenia (FN) during breast cancer treatment. The aims of this study were to evaluate the incidence of FN and the ANC profile in patients undergoing chemotherapy and pegfilgrastim primary prophylaxis.MethodsPatients receiving 6 cycles of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy were included in this study. Pegfilgrastim was administered with analgesics 24 hours after treatment. Laboratory tests were performed on day 0 (before chemotherapy) and ANC was measured daily starting day 5 until it were restored to 1,000/mm3. Bone pain was checked via the numeral rating scale (NRS).ResultsA total of 61 patients and 366 cycles were evaluated. Mean age was 49.2 ± 7.1 years. FN was seen in 5 patients (16.4%) and 12 cycles (3.3%) with pegfilgrastim. Grades 3 and 4 neutropenia was seen in 91.5% of cycles with FN. The ANC nadir was most commonly seen at day 7 and the mean ANC nadir depth was 265.7/m3. Age was negatively correlated with nadir depth (r = −0.137, P = 0.009). Severe pain higher than NRS 7 occurred in less than 20% of patients after the administration of pegfilgrastim.ConclusionIncidence of FN was low during the chemotherapy by primary prophylaxis with pegfilgrastim. The ANC nadir was seen on day 7 after chemotherapy. Bone pain with pegfilgrastim was well tolerated during TAC chemotherapy.

show abstract

Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia

Cited by 16 publications

References 67 publications

Estudio FIRES: Filgrastim - investigación retrospectiva de efectividad y seguridad en una institución de salud en Colombia

Estudio FIRES: Filgrastim - investigación retrospectiva de efectividad y seguridad en una institución de salud en Colombia

The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy

Contact Info

Product

Resources

About